ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
23.77
+0.37 (1.58%)
At close: Mar 9, 2026, 4:00 PM EDT
24.40
+0.63 (2.65%)
After-hours: Mar 9, 2026, 5:03 PM EDT
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
213.16M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcturus Therapeutics Holdings | 82.03M |
| Protalix BioTherapeutics | 61.84M |
| Voyager Therapeutics | 31.32M |
| MediWound | 16.96M |
| Cibus | 3.79M |
| Camp4 Therapeutics | 3.50M |
| Humacyte | 1.57M |
PMN News
- 4 weeks ago - ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 5 weeks ago - ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces Reverse Stock Split - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights - GlobeNewsWire